Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Apple Turns 50: From Garage Startup to AI Crossroads 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
SAN CARLOS, Calif., Sept. 05, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will webcast a business overview and update by Dr. Maria Fardis, PhD, MBA, Chief Executive Officer of Iovance Biotherapeutics at the following upcoming investor conferences:
- Rodman & Renshaw 19th Annual Global Investment Conference in New York, NY on Monday, September 11, 2017 at 11:40 a.m. ET
- 2017 Cantor Fitzgerald Global Healthcare Conference in New York, NY on Monday, September 25, 2017 at 8:00 a.m. ET
A live audio webcast of both presentations will be available by visiting the Investors section Iovance Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcast will be archived on Iovance Biotherapeutics’ website for 30 days following the presentation.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit http://www.iovance.com.
Investor Relations Contact: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected] Media Relations Contact: Evan Smith/Kotaro Yoshida FTI Consulting 212-850-5622/212-850-5690 [email protected] [email protected]
